Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 280, Issue 4 49-4, 2001, Pages

  Zhao, Yongqiang ^a   Qiu, Qianyao ^a   Mahdi, Fakhri ^a   Shariat Madar, Zia ^a   Røjkær, Rasmus ^a   Schmaier, Alvin H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Kallikrein; Kininogen; Nitric oxide; Prekallikrein; Zinc

Indexed keywords

4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; ANTIPAIN; BOVINE SERUM ALBUMIN; BRADYKININ; BRADYKININ B2 RECEPTOR; KININOGEN; LISINOPRIL; NITRIC OXIDE; PREKALLIKREIN; ZINC;

ARTICLE; BINDING SITE; DISSOCIATION CONSTANT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0035019596     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2001.280.4.h1821     Document Type: Article

References (34)

1. Bax CMR and Bloxam DL. Human fetal endothelial cells acquire zinc from both the protein bound and nonprotein bound pools in serum. Biol Trace Elem Res 56: 255-271, 1997.
2. Berrettini. M, Schleef RR, Heeb MJ, Hopmeier P, and Griffin JH. Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells. J Biol Chem 267: 19833-19839, 1992.
3. Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, and McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 100: 1481-1487, 1997.
4. Cunningham BC, Bass S, Fuh G, and Wells JA. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 250: 709-1712, 1990.
5. DeLa Cadena RA and Colman RW. The sequence HGLGH-GHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface. Protein Sci 1: 151-160, 1992.
6. Gorodetsky R, Mou X, Blankenfeld A, and Marx G. Platelet multielemental composition, lability, and subcellular localization. Am J Hematol 42: 278-283, 1993.
7. Greengard JS and Griffin JH Receptors for high molecular weight kininogen on stimulated washed human platelets. Biochemistry 23: 6863-6869, 1984.
8. Gustafson EJ, Schutsky D, Knight LC, and Schmaier AH. High molecular weight kininogen binds to unstimulated platelets. J Clin Invest 78: 310-318, 1986.
9. Hasan AAK, Cines DB, Zhang J, and Schmaier AH. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. J Biol Chem 268: 31822-31830, 1994.
10. Hasan AAK, Cines DB, Ngaiza JR, Jaffe EA, and Schmaier AH. High-molecular-weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium. Blood 85: 3134-3143, 1995.
11. Hasan AAK, Zisman T, and Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci USA 95: 3615-3620, 1998.
12. Hevel JM and Marietta MA. Nitric-oxide synthesis assays. Methods Enzymol 233: 250-258, 1994.
13. Jaffe EA, Nachman RL, Becker CG, and Minick CR. Culture of human endothelial cells derived from umbilical cord veins. J Clin Invest 52: 2745-2756, 1973.
14. Jiang Y, Muller-Esterl W, and Schmaier AH. Domain 3 of kininogens contains a cell binding site and a site that modifies thrombin activation of platelets. J Biol Chem 267: 3712-3717, 1992.
15. Joseph K, Ghebrehiwet B, Peerschke EIB, Reid KBM, and Kaplan AP. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc Natl Acad Sci USA 93: 8552-8557, 1996.
16. Lin Y, Harris RB, Yan W, McCrae KR, Zhang H, and Colman RW. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood 90: 690-697, 1997.
17. Meloni FJ and Schmaier AH. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 266: 6786-6794, 1991.
18. Meloni FJ, Gustafson EJ, and Schmaier AH. High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. Blood 79: 1233-1244, 1992.
19. Motta G, Rojkjaer R, Hasan AAK, Cines DB, and Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 91: 516-528, 1998.
20. Muller-Esterl W. Immunological probes for the bradykinin B2 receptor. A toolbox. In: The Kinin System, edited by Farmer SG. San Diego, CA: Academic, 1997, p. 99-110.
21. Nishikawa K, Shibayama Y, Kuna P, Calcaterra E, Kaplan AP, and Reddigari SR. Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein. Blood 80: 1980-1988, 1992.
22. Palmer RM, Ferrige AG, and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526, 1998.
23. Reddigari SR, Kuna P, Miragliotta G, Shibayama Y, Nishikawa K, and Kaplan AP. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood 81: 1306-1311, 1993.
24. Roche Silva M, Beraldo WT, and Rosenfeld G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol 156: 261-273, 1949.
25. 2+-binding sites in factor XII and its derivatives. Eur J Biochem 247: 491-496, 1997.
26. Rojkjaer R, Hasan AAK, Motta G, Schousboe I, and Schmaier AH. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 80: 74-81, 1998.
27. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660-672, 1949.
28. Schmaier AH, Kuo A, Lundberg D, Murray S, and Cines DB. Expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 263: 16327-16333, 1988.
29. Schmaier AH, Farber A, Schein R, and Sprung C. Structural changes of plasma high molecular weight kininogen after in vitro activation and in sepsis. J Lab Clin Med 112: 182-192, 1988.
30. Van Iwaarden F, de Groot PG, Sixma JJ, Berrettini M, and Bouna BN. High-molecular weight kininogen is present in cultured human endothelial cells: Localization, isolation and characterization. Blood 71: 1268-1276, 1988.
31. Van Iwaarden F, de Groot PG, and Bouma BN. The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem 263: 4697-4703, 1988.
32. Weisel JW, Nagaswami C, Woohead JL, DeLa Cadena RA, Page JD, and Colman RW. The shape of high molecular weight kininogen: organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem 269: 10100-10106, 1994.
33. Whitehouse RC, Prasad AS, Rabbani PI, and Cossack ZT. Zinc in plasma, neutrophils, lymphocytes, and erythrocytes as determined by flameless atomic absorption spectrophotometry. Clin Chem 28: 475-480, 1982.
34. Zini JM, Schmaier AH, and Cines DB. Bradykinin regulates the expression of kininogen binding sites on endothelial cells. Blood 81: 2936-2946, 1993.